Zhejiang Zhaohua Biopharmaceutical

Zhaohua Biopharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of innovative recombinant vaccines. The company utilizes advanced protein engineering and CHO cell expression platforms to create high-efficacy vaccines for infectious diseases, including shingles, HPV, and RSV. Its lead candidate, a recombinant herpes zoster vaccine, is currently undergoing Phase 2 clinical trials, positioning the company as a significant player in the Chinese vaccine market. Zhaohua is supported by prominent investors such as SDIC Fund Management and is expanding its manufacturing capabilities to support large-scale production. The company aims to address global health challenges by providing accessible and high-quality immunization solutions.